Trials / Completed
CompletedNCT00676884
A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Aerovance, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to investigate the effect of AERODERM (also known as pitrakinra, AER 001, BAY 16-9996) on Eczema Area and Severity Index (EASI) score in subjects with moderate to severe atopic eczema
Detailed description
The primary objective of this study is to investigate the effect of AERODERM (also known as pitrakinra, AER 001, BAY 16-9996) on Eczema Area and Severity Index (EASI) score in subjects with moderate to severe atopic eczema in a randomised, placebo controlled, parallel-group study with bid sc. dosing of AERODERM for 28 days
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996) | 30 mgs s.c. b.i.d. |
| DRUG | placebo | 1.5 mL s.c. b.i.d. |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2006-07-01
- Completion
- 2006-08-01
- First posted
- 2008-05-13
- Last updated
- 2008-05-13
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00676884. Inclusion in this directory is not an endorsement.